BGPartner advises Memo Therapeutics Ltd on its CHF 25 million Series C financing round

02. November 2023

Memo Therapeutics Ltd is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer. MTx will use the proceeds to complete U.S. Phase II clinical development of its best- and first-in-class antibody, AntiBKV, intended to neutralize BK polyomavirus (BKV) infection in kidney transplant recipients.

The Series C financing round was led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group, Fresenius Medical Care Ventures and Red Alpine joined in the round.

The BGPartner team assisting Memo Therapeutics Ltd in all legal and negotiation matters was led by Oliver Gnehm (Partner) and further consisted of Victoria Marty (Associate) and Barbara Meise (Associate).

BGPartner is a top Swiss law firm in the area of Private Equity and Venture Capital and has won various awards.

Click here for the complete media release.

More information about our legal and negotiation expertise can be found here.